NASDAQ:SABS | Cash Flow Statement | SAB Biotherapeutics, Inc.

Complete source-backed cash-flow history.

Available history
2020-12-31 to 2026-06-30
Data captured

Historical Cash Flow Statement

DateNet incomeDepreciation and amortizationOperating cash flowCapital expenditureInvesting cash flowShare repurchasesDividends paidFinancing cash flow
2026-06-30-$22.49M$800,000.00
2026-03-31-$18.87M$730,965.00-$14.27M$983,257.00-$65.65M$89.92M
2025-12-31-$16.86M$741,593.00-$16.78M-$1.71M-$41,685.00
2025-09-30$45.45M$700,000.00
2025-06-30-$10.11M$800,000.00
2025-03-31-$5.2M$756,595.00-$7.8M$4.67M-$173,985.00
2024-12-31-$11.39M$764,007.00-$9.53M$55,377.00$9.33M$216,961.00
2024-09-30-$10.35M$900,000.00
2024-06-30-$7.34M$1M
2024-03-31-$5.03M$1.96M-$10.75M$129,074.00-$31.36M-$394,418.00
2023-12-31-$22.86M$922,491.00-$13.45M$67,864.00-$67,864.00$67.64M
2023-09-30-$5.1M$1M
2023-06-30-$6.88M$900,000.00
2023-03-31-$7.35M$898,453.00-$1.61M$21,300.00-$21,300.00-$359,790.00
2022-12-31-$7.87M$898,808.00-$1.56M$117,754.00-$117,754.00$8.39M
2022-09-30-$7.08M$890,000.00
2022-06-30-$4.78M$750,000.00
2022-03-31$985,863.00$636,235.00-$9.54M$1.36M-$1.28M-$6.32M
2021-12-31-$11.55M$619,984.00-$4.88M$2.36M-$2.36M$36.03M
2021-09-30-$4.06M$369,366.00
2021-06-30-$2.94M$258,891.00
2021-03-31$1.41M$235,959.00$9.45M$1.89M-$1.89M-$45,471.00

Annual Cash Flow Statement

DateNet incomeDepreciation and amortizationOperating cash flowCapital expenditureInvesting cash flowShare repurchasesDividends paidFinancing cash flow
2025-12-31$13.27M$2.99M-$44.78M$933,156.00-$121.71M$168.3M
2024-12-31-$34.11M$4.71M-$34.29M$337,262.00-$11.96M-$1.17M
2023-12-31-$42.19M$3.65M-$25.12M$197,154.00-$152,704.00$66.77M
2022-12-31-$18.74M$3.17M-$23.46M$2.17M-$2.09M$1.05M
2021-12-31-$17.14M$1.49M$1.99M$10.94M-$10.94M$35.89M
2020-12-31$20.12M$383,142.00$10M$12.73M-$12.72M$8.98M

Research interface only. Not investment advice. Prices are a checked-in snapshot, not live quotes.